Imaging of VEGF receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma model

Neoplasia

Volumn 7, Issue 9, 2005, Pages 847-853

  Reichardt, Wilfried ^a   Hu Lowe, Dana ^b   Torres, Denise ^a   Weissleder, Ralph ^a   Bogdanov Jr , Alexei ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Iron oxide; MRI; Tumor blood volume; VEGFR2 inhibitor

Indexed keywords

NANOPARTICLE; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR KINASE INHIBITOR; AG 013925; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FERRIC ION; FERRIC OXIDE; INDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ADENOCARCINOMA; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VOLUME; COLON CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PRIORITY JOURNAL; SKELETAL MUSCLE; XENOGRAFT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; EVALUATION; FEMALE; METHODOLOGY; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD VOLUME; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FERRIC COMPOUNDS; HUMANS; INDAZOLES; MAGNETIC RESONANCE IMAGING; MICE; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33644873507     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05139     Document Type: Article

References (45)

1. Kerbel R (2004). Antiangiogenic drugs and current strategies for the treatment of lung cancer. Semin Oncol 31, 54-60.
2. McCarty M, Liu W, Fan F, Parikh A, Reimuth N, Stoeltzing O, and Ellis L (2003). Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends Mol Med 9, 53-58.
3. Santos SC and Dias S (2004). Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 103, 3883-3889.
4. Steiner H, Berger AP, Godoy-Tundidor S, Bjartell A, Lilja H, Bartsch G, Hobisch A, and Culig Z (2004). An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. Eur J Cancer 40, 1066-1072.
5. Ciardiello F, Caputo R, Damiano V, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, and Tortora G (2003). Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9, 1546-1556.
6. Vajkoczy P, Menger MD, Vollmar B, Schilling L, Schmiedek P, Hirth KP, Ullrich A, and Fong TA (1999). Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia (New York) 1, 31-41.
7. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, et al. (2000). SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60, 4152-4160.
8. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, and Ellis LM (1999). Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 59, 5412-5416.
9. Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, and Cherrington JM (2000). The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 6, 4848-4858.
10. Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M, Wood J, Martiny-Baron G, Unger C, and Marme D (2000). Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60, 4819-4824.
11. Drevs J, Muller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, Konerding MA, Allegrini PR, Wood J, Hennig J, et al. (2002). PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62, 4015-4022.
12. Fabbro D, Buchdunger E, Wood J, Mestan J, Hofmann F, Ferrari S, Mett H, O'Reilly T, and Meyer T (1999). Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther 82, 293-301.
13. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O'Reilly T, and Meyer T (2000). PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anti-Cancer Drug Des 15, 17-28.
14. Tetsuichiro I, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe D, Shalinsky D, Thurston G, Yancopoulos G, et al. (2004). Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165, 35-52.
15. Neeman M, Provenzale J, and Dewhirst M (2001). Magnetic resonance imaging applications in the evaluation of tumor angiogenesis. Semin Rad Oncol 11, 70-82.
16. Neeman M (2002). Functional and molecular MR imaging of angiogenesis: seeing the target, seeing it work. J Cell Biochem 39, 11-17.
17. McDonald DM and Choyke PL (2003). Imaging of angiogenesis: from microscope to clinic. Nat Med 9, 713-725.
18. Lin W, Paczynski RP, Kuppusamy K, Hsu CY, and Haacke EM (1997). Quantitative measurements of regional cerebral blood volume using MRI in rats: effects of arterial carbon dioxide tension and mannitol. Magn Reson Med 38, 420-428.
19. Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CH, Ferraro JA, Zalles CM, Stanton AL, Masood S, Grizzle WE, et al. (2002). A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 8, 3105-3117.
20. Bruening R, Kwong KK, Vevea MJ, Hochberg FH, Cher L, Niemi PT, Weisskoff RM, and Rosen BR (1996). Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting. Am J Neuroradiol 17, 831-840.
21. Maeda M, Itoh S, Kimura H, Iwasaki T, Hayashi N, Yamamoto K, Ishii Y, and Kubota T (1993 (October)). Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology 189, 233-238.
22. Mandeville JB, Marota JJ, Kosofsky BE, Keltner JR, Weissleder R, Rosen BR, and Weisskoff RM (1998). Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation. Magn Reson Med 39, 615-624.
23. Dennie J, Mandeville J, Boxerman J, Packard S, Rosen B, and Weisskoff R (1998). NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 40, 793-799.
24. Bremer C, Mustafa M, Bogdanov A, Jr, Ntziachristos V, Petrovsky A, and Weissleder R (2003). Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. Radiology 226, 214-220.
25. Petrovsky A, Schellenberger E, Josephson L, Weissleder R, and Bogdanov A Jr (2003). Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res 63, 1936-1942.
26. Wunderbaldinger P, Josephson L, and Weissleder R (2002). Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjug Chem 13, 264-268.
27. Zhu H, Melder R, Baxter L, and Jain R (1996). Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy. Cancer Res 56, 3771-3781.
28. Shen T, Weissleder R, Papisov M, Bogdanov A, Jr, and Brady TJ (1993). Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. Magn Reson Med 29, 599-604.
29. McLachlan SJ, Morris MR, Lucas MA, Fisco RA, Eakins MN, Fowler DR, Scheetz RB, and Olukotun AY (1994). Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 4, 301-307.
30. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, and Weissleder R (2003). Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348, 2491-2499.
31. Schnorr J, Wagner S, Abramjuk C, Wojner I, Schink T, Kroencke TJ, Schellenberger E, Hamm B, Pilgrimm H, and Taupitz M (2004). Comparison of the iron oxide-based blood-pool contrast medium VSOP-C184 with gadopentetate dimeglumine for first-pass magnetic resonance angiography of the aorta and renal arteries in pigs. Invest Radiol 39, 546-553.
32. Trivedi RA, Graves UK-I, Cross MJ, Horsley JJ, Goddard J, Skepper MJ, Quartey JN, Warburton G, Joubert E, Wang I, et al. (2004). In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke 35, 1631-1635.
33. Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, Radeleff J, Magener A, Brix G, Delorme S, Zuna I, et al. (1999). Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10, 260-266.
34. Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, Lu Y, and Brasch RC (1998). Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. Am J Roentgenol 171, 941-949.
35. Jayson G, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G, et al. (2002). Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94, 1484-1493.
36. Izumi Y, Xu L, di Tomaso E, Fukumura D, and Jain RK (2002). Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416, 279-280.
37. Schmiedl U, Ogan M, Paajanen H, Marott M, Crooks LE, Brito A, and Brasch RC (1987). Albumin labeled with Gd-DTPA as an intravascular, blood pool-enhancing agent for MR imaging: biodistribution and imaging studies. Radiology 162, 205-210.
38. Donahue KM, Weisskoff RM, Chesler DA, Kwong KK, Bogdanov AA Jr, Mandeville JB, and Rosen BR (1996). Improving MR quantification of regional blood volume with intravascular T1 contrast agents: accuracy, precision, and water exchange. Magn Reson Med 36, 858-867.
39. Bhujwalla ZM, Artemov D, Natarajan K, Solaiyappan M, Kollars P, and Kristjansen PE (2003). Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 9, 355-362.
40. Kim Y, Rebro K, and Schmainda K (2002). Water exchange and inflow affect the accuracy of T1-GRE blood volume measurements: implication for the evaluation of tumor angiogenesis. Magn Reson Med 47, 1110-1120.
41. Hu-Lowe D, Heller D, Feeley R, Reed J, Zou H, Hallin M, Rewolinski D, Grove C, Braganza J, Kania R, et al. (2001). A small molecule inhibitor of vascular endothelial growth factor receptor tyrosine kinase. In Proceedings. AACR, San Francisco, CA. p. 3134.
42. Turetschek K, Preda A, Floyd E, Shames DM, Novikov V, Roberts TP, Wood JM, Fu Y, Carter WO, and Brasch RC (2002). MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model. Acad Radiol 9, S519-S520.
43. Jain RK (2001). Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7, 987-989.
44. Doherty N and Beaver T (1990). Comparison of the anaphylactoid response induced in rats by castanospermine and dextran. Int Arch Allergy Appl Immunol 93, 19-25.
45. Harika L, Weissleder R, Poss K, and Papisov M (1996). Macromolecular intravenous contrast agent for MR lymphography: characterization and efficacy studies. Radiology 198, 365-370.